Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2008 1
2009 1
2011 1
2013 4
2014 1
2015 1
2016 3
2017 1
2018 2
2019 6
2020 2
2021 4
2022 6
2023 1
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.
Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Moluçon-Chabrot C, Schmitt A, Gressin R, Choquet S, Damaj G, Peyrade F, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Al Jijakli A, Morel P, Waultier A, Paillassa J, Chauchet A, Gastinne T, Laadhari M, Plissonnier AS, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; LOC Network for CNS Lymphoma. Houillier C, et al. Among authors: molucon chabrot c. J Clin Oncol. 2022 Nov 10;40(32):3692-3698. doi: 10.1200/JCO.22.00491. Epub 2022 Jul 14. J Clin Oncol. 2022. PMID: 35834762 Clinical Trial.
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, Nicolas-Virelizier E, Barrie M, Moluçon-Chabrot C, Lelez ML, Clavert A, Coisy S, Leruez S, Touitou V, Cassoux N, Daniau M, Ertault de la Bretonnière M, El Yamani A, Ghesquières H, Hoang-Xuan K. Soussain C, et al. Among authors: molucon chabrot c. Eur J Cancer. 2019 Aug;117:121-130. doi: 10.1016/j.ejca.2019.05.024. Epub 2019 Jul 3. Eur J Cancer. 2019. PMID: 31279304 Clinical Trial.
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C. Ghesquieres H, et al. Among authors: molucon chabrot c. Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. Ann Oncol. 2019. PMID: 30698644 Free article. Clinical Trial.
Deciphering Unexpected Vascular Locations of Scedosporium spp. and Lomentospora prolificans Fungal Infections, France.
Vignals C, Emmerich J, Begueret H, Garcia-Hermoso D, Martin-Blondel G, Angoulvant A, Blez D, Bruneval P, Cassaing S, Catherinot E, Cahen P, Moluçon-Chabrot C, Chevenet C, Delhaes L, Escaut L, Faruch M, Grenouillet F, Larosa F, Limousin L, Longchampt E, Mellot F, Nourrisson C, Bougnoux ME, Lortholary O, Roux A, Rozenblum L, Puges M, Lanternier F, Bronnimann D. Vignals C, et al. Among authors: molucon chabrot c. Emerg Infect Dis. 2024 Jun;30(6):1077-1087. doi: 10.3201/eid3006.231409. Emerg Infect Dis. 2024. PMID: 38781681 Free PMC article. Review.
[Major therapeutic advances and new perspectives in onco-hematology].
Bay JO, Guièze R, Ravinet A, Lemal R, Xhaard A, Bailly S, Moluçon-Chabrot C, Hermet E, Biau J, Verrelle P, Peffault de Latour R, Tournilhac O. Bay JO, et al. Among authors: molucon chabrot c. Bull Cancer. 2013 Jun;100(6):587-99. doi: 10.1684/bdc.2013.1751. Bull Cancer. 2013. PMID: 23735575 Review. French.
[Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].
Brotelle T, Lemal R, Moluçon-Chabrot C, Bay JO, Delaunay J, Guièze R. Brotelle T, et al. Among authors: molucon chabrot c. Bull Cancer. 2014 Feb;101(2):211-8. doi: 10.1684/bdc.2014.1886. Bull Cancer. 2014. PMID: 24557850 Review. French.
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
Bachy E, Houot R, Feugier P, Bouabdallah K, Bouabdallah R, Virelizier EN, Maerevoet M, Fruchart C, Snauwaert S, Le Gouill S, Marolleau JP, Molina L, Moluçon-Chabrot C, Thieblemont C, Tilly H, Bijou F, Haioun C, Van den Neste E, Fabiani B, Meignan M, Cartron G, Salles G, Casasnovas O, Morschhauser F. Bachy E, et al. Among authors: molucon chabrot c. Blood. 2022 Apr 14;139(15):2338-2346. doi: 10.1182/blood.2021013526. Blood. 2022. PMID: 34936697 Free article.
SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era.
Laurenge A, Ursu R, Tabouret E, Harlay V, Ahle G, Choquet S, Soussain C, Moluçon-Chabrot C, Mathon B, Mokhtari K, Pourcher V, Nichelli L, Marot S, Touat M, Hoang-Xuan K, Houillier C. Laurenge A, et al. Among authors: molucon chabrot c. Leuk Lymphoma. 2023 Jan;64(1):221-224. doi: 10.1080/10428194.2022.2131420. Epub 2022 Nov 1. Leuk Lymphoma. 2023. PMID: 36318828 No abstract available.
35 results